Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000136

Drug Information
NameINO-1001
SynonymsKBio2_002444; KBioSS_002450; AC1O8FMH; KBio2_007580; BSPBio_002719; Hypoxanthine arabinoside; SPECTRUM3100024; AC-3200; DivK1c_006781; Spectrum5_000469; KBio3_002219; SPBio_001977; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one; CHEMBL462399; Spectrum_001910; Spectrum3_001160; CID6708742; KBioGR_002372; KBio2_005012; LT00454797; KBio1_001725; INO-1001; Spectrum2_001939; SpecPlus_000685; Spectrum4_001795
CompanyInotek Pharma.
IndicationBrain CancerPhase I/II    
Myocardial infarction, Cardiovascular Disorders
[ICD9: 390-459, 410   ICD10: I00-I99, I21, I22]
Phase II    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(
5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10?/m1/s1
InChIKeyUGQMRVRMYYASKQ-VTHZCTBJSA-N
Canonical SMILESC1=NC(=O)C2=C(N1)N(C=N2)C3C(C(C(O3)CO)O)O    
Isomeric SMILESC1=NC(=O)C2=C(N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CO)O)O
Therapeutic ClassAntineoplastic Agents
PubChem Compound IDCID 6708742.
PubChem Substance IDSID 11341956.
SuperDrug ATC IDC03CA03
SuperDrug CAS ID055837279;
ClinicalTrials.govNCT00271167;
NCT00271765;
TargetPoly [ADP-ribose] polymerase 1Inhibitor[1][2][3][4]
Ref 1A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 2009 Aug;27(7):756-63. To Reference
Ref 2J Thromb Thrombolysis. 2009 May;27(4):359-64. Epub 2008 Jun 6.A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. To Reference
Ref 3Poly (ADP) ribose synthetase inhibition in alveolar macrophages undergoing hypoxia and reoxygenation. Exp Mol Pathol. 2008 Apr;84(2):141-4. Epub 2007 Dec 7. To Reference
Ref 4Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543